Want to see AU:IDX full AI Analyst Report?
Top Page
Integral Diagnostics Ltd.
(Sydney:IDX)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$2.00
▼(-11.50% Downside)
Action:Reiterated
Date:10/04/25
Integral Diagnostics Ltd. has strong revenue growth and operational efficiency, but faces significant challenges in profitability and cash flow management. The technical indicators suggest bearish momentum, and the stock appears overvalued with a high P/E ratio. These factors contribute to a cautious outlook, reflected in the overall score.
Positive Factors
Revenue Growth
Sustained double-digit revenue growth indicates expanding patient volumes and stronger utilisation of the clinic and hospital network. This durable top-line expansion supports scale economics, funds reinvestment in imaging equipment and sites, and underpins growth momentum over months.
Negative Factors
Low Net Margin
A sub-1% net margin shows the business struggles to convert strong top-line growth into durable profits after overhead and non-operating costs. This limits retained earnings for reinvestment, constrains shareholder returns, and increases vulnerability to rising costs or reimbursement pressure over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained double-digit revenue growth indicates expanding patient volumes and stronger utilisation of the clinic and hospital network. This durable top-line expansion supports scale economics, funds reinvestment in imaging equipment and sites, and underpins growth momentum over months.
Read all positive factors
Integral Diagnostics Ltd. (IDX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$771.80M
Dividend Yield2.65%
Average Volume (3M)911.20K
Price to Earnings (P/E)56.1
Beta (1Y)0.62
Revenue Growth56.28%
EPS Growth55.14%
CountryAU
Employees3,000
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.04
Shares Outstanding373,066,530
10 Day Avg. Volume1,057,226
30 Day Avg. Volume911,197
Financial Highlights & Ratios
PEG Ratio-1.58
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio55.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.13Price Target Upside38.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.15
Revenue Forecast (FY)AU$849.38M
Integral Diagnostics Ltd. Business Overview & Revenue Model
Company Description
Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services. These services are delivered to general practitioners, medical specialists, allied health professionals, and their patients across...
How the Company Makes Money
IDX primarily makes money by performing diagnostic imaging examinations and providing radiology reporting services, earning fees per scan/study delivered to patients referred by clinicians and hospitals. Revenue is generated across multiple modali...
Integral Diagnostics Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
65
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 767.82M | 627.22M | 469.70M | 440.10M | 358.74M | 348.81M |
| Gross Profit | 170.25M | 599.09M | 446.78M | 97.76M | 83.84M | 92.19M |
| EBITDA | 131.67M | 87.70M | 12.10M | 92.74M | 69.90M | 88.94M |
| Net Income | 14.03M | 4.67M | -60.70M | 25.04M | 14.60M | 31.27M |
Balance Sheet | ||||||
| Total Assets | 1.42B | 1.43B | 744.28M | 839.01M | 783.01M | 654.90M |
| Cash, Cash Equivalents and Short-Term Investments | 34.12M | 52.10M | 42.44M | 33.85M | 123.19M | 62.20M |
| Total Debt | 841.54M | 585.01M | 355.59M | 365.08M | 340.99M | 308.36M |
| Total Liabilities | 742.06M | 732.53M | 442.57M | 465.96M | 435.77M | 400.16M |
| Stockholders Equity | 678.25M | 693.00M | 301.71M | 373.05M | 347.24M | 254.74M |
Cash Flow | ||||||
| Free Cash Flow | 26.69M | 14.01M | 42.28M | 27.42M | 9.33M | 49.30M |
| Operating Cash Flow | 84.45M | 73.77M | 66.16M | 71.42M | 37.10M | 69.57M |
| Investing Cash Flow | -56.25M | -64.99M | -27.90M | -128.96M | -55.69M | -56.66M |
| Financing Cash Flow | -24.89M | 710.00K | -29.45M | -31.85M | 81.13M | -7.83M |
Integral Diagnostics Ltd. Technical Analysis
Positive
2.26
Price Trends
2.08
Positive
2.20
Negative
2.36
Negative
Market Momentum
<0.01
Negative
56.98
Neutral
71.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDX, the sentiment is Positive. The current price of 2.26 is above the 20-day moving average (MA) of 2.03, above the 50-day MA of 2.08, and below the 200-day MA of 2.36, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.98 is Neutral, neither overbought nor oversold. The STOCH value of 71.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IDX.
Integral Diagnostics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$10.58B | 19.45 | 6.39% | 4.69% | 13.14% | -2.73% | |
59 Neutral | AU$427.13M | 15.06 | 16.35% | 4.60% | 1.12% | -12.02% | |
55 Neutral | AU$771.80M | 56.12 | 2.05% | 2.65% | 56.28% | 55.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$290.46M | -0.53 | -29.48% | ― | -12.15% | -2285.99% | |
42 Neutral | AU$5.94M | -0.71 | 142.99% | ― | -100.00% | 68.62% | |
39 Underperform | AU$28.02M | -3.82 | -164.22% | ― | ― | 26.04% |
* Healthcare Sector Average
AU:IDX
Integral Diagnostics Ltd.
2.10
-0.49
-18.86%
AU:HLS
Healius Limited
0.39
-0.37
-48.34%
AU:BDX
BCAL Diagnostics Limited
0.08
<0.01
8.57%
AU:SHL
Sonic Healthcare Limited
21.48
-4.57
-17.54%
AU:ACL
Australian Clinical Labs Ltd
2.27
-0.43
-15.99%
AU:IBX
Imagion Biosystems Ltd.
0.01
>-0.01
-31.25%
Integral Diagnostics Ltd. Corporate Events
Integral Diagnostics Director Increases Shareholding via Incentive Vesting
Jul 1, 2026
Integral Diagnostics has reported a change in the shareholding of director Ian Kadish following the vesting of short-term incentive performance rights. Kadish converted 37,678 STI performance rights into an equal number of fully paid ordinary shar...
Integral Diagnostics Issues 67,226 New Ordinary Shares After Option Conversions
Jul 1, 2026
Integral Diagnostics Ltd. has issued 67,226 new ordinary fully paid shares following the conversion or exercise of previously unquoted equity securities. The issuance, notified to the ASX under Appendix 3G and effective 1 July 2026, modestly incre...
Integral Diagnostics Director Increases Shareholding via On-Market Purchase
Jun 25, 2026
Integral Diagnostics Ltd. reported a change in the shareholding of director James Tobias Hall, reflecting an increase in his direct ownership of the company’s ordinary shares. The on-market purchase aligns his financial interests more closel...
Integral Diagnostics to Release 178,146 Escrowed Shares Without Capital Change
Jun 19, 2026
Integral Diagnostics will release 178,146 fully paid ordinary shares from voluntary escrow on 1 July 2026, in line with market disclosure requirements. The move does not alter the company’s issued capital, indicating no immediate dilution fo...
Integral Diagnostics orders audit after rebutting WA billing allegations
Jun 9, 2026
Integral Diagnostics has responded to media reports in Western Australia alleging inappropriate Medicare billing by its subsidiary Apex Radiology at Kalgoorlie Hospital, stating it is not aware of any improper practices. The company highlighted it...
Australian Retirement Trust exits substantial holder status in Integral Diagnostics
May 21, 2026
Australian Retirement Trust Pty Ltd, acting as trustee for Australian Retirement Trust, has notified Integral Diagnostics that it has ceased to be a substantial shareholder in the company as of 19 May 2026. The change in relevant interest, detaile...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.